SHATTUCK LABS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.59 USD | +8.28% |
|
+10.54% | +48.53% |
| Mar. 04 | Shattuck Labs, Inc. Announces Board Appointments | CI |
| Mar. 01 | Sector Update: Health Care Stocks Rising Late Afternoon | MT |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Shattuck Labs...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.59
USD
Average target price
15.75
USD
Spread / Average Target
+48.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +48.53% | 504M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- STTK Stock
- News Shattuck Labs, Inc.
- Transcript : Shattuck Labs, Inc., Q3 2023 Earnings Call, Nov 09, 2023
